Dacomitinib is an investigational drug used in the treatment of non-small cell lung cancer. It is important to ensure that the drug is pure and free of impurities that can affect its safety and efficacy. Dacomitinib impurities are defined as any substance present in the drug substance that is not the active pharmaceutical ingredient. These impurities can arise during the manufacturing process, storage, or transportation. It is essential to monitor and control the levels of impurities in dacomitinib to
